Northwest Biotherapeutics Past Earnings Performance
Past criteria checks 0/6
Northwest Biotherapeutics has been growing earnings at an average annual rate of 7%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 9.4% per year.
Key information
7.0%
Earnings growth rate
13.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 9.4% |
| Return on equity | n/a |
| Net Margin | -3,331.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Northwest Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -64 | 30 | 0 |
| 30 Sep 23 | 2 | -73 | 31 | 0 |
| 30 Jun 23 | 2 | -87 | 32 | 0 |
| 31 Mar 23 | 2 | -102 | 32 | 0 |
| 31 Dec 22 | 2 | -105 | 33 | 0 |
| 30 Sep 22 | 1 | 57 | 30 | 0 |
| 30 Jun 22 | 1 | 135 | 29 | 0 |
| 31 Mar 22 | 1 | 169 | 28 | 0 |
| 31 Dec 21 | 1 | 179 | 33 | 0 |
| 30 Sep 21 | 2 | -234 | 42 | 0 |
| 30 Jun 21 | 1 | -474 | 66 | 0 |
| 31 Mar 21 | 1 | -537 | 63 | 0 |
| 31 Dec 20 | 1 | -530 | 54 | 0 |
| 30 Sep 20 | 2 | -243 | 43 | 0 |
| 30 Jun 20 | 2 | -56 | 16 | 0 |
| 31 Mar 20 | 3 | 3 | 16 | 0 |
| 31 Dec 19 | 2 | -21 | 16 | 0 |
| 30 Sep 19 | 1 | -33 | 15 | 0 |
| 30 Jun 19 | 1 | -18 | 16 | 0 |
| 31 Mar 19 | 1 | -43 | 28 | 0 |
| 31 Dec 18 | 0 | -54 | 27 | 0 |
| 30 Sep 18 | 1 | -76 | 30 | 0 |
| 30 Jun 18 | 1 | -108 | 29 | 0 |
| 31 Mar 18 | 0 | -93 | 19 | 0 |
| 31 Dec 17 | 0 | -74 | 21 | 0 |
| 30 Sep 17 | 0 | -77 | 21 | 0 |
| 30 Jun 17 | 0 | -86 | 21 | 0 |
| 31 Mar 17 | 0 | -92 | 22 | 0 |
| 31 Dec 16 | 1 | -86 | 20 | 0 |
| 30 Sep 16 | 1 | -79 | 21 | 0 |
| 30 Jun 16 | 2 | -24 | 21 | 0 |
| 31 Mar 16 | 2 | -74 | 26 | 0 |
| 31 Dec 15 | 2 | -115 | 25 | 0 |
| 30 Sep 15 | 2 | -133 | 24 | 0 |
| 30 Jun 15 | 2 | -177 | 24 | 0 |
| 31 Mar 15 | 2 | -136 | 17 | 0 |
| 31 Dec 14 | 1 | -136 | 17 | 0 |
| 30 Sep 14 | 1 | -110 | 16 | 0 |
| 30 Jun 14 | 0 | -112 | 14 | 0 |
| 31 Mar 14 | 1 | -97 | 14 | 0 |
| 31 Dec 13 | 1 | -66 | 12 | 0 |
| 30 Sep 13 | 1 | -79 | 16 | 0 |
| 30 Jun 13 | 1 | -73 | 17 | 0 |
Quality Earnings: NWBO is currently unprofitable.
Growing Profit Margin: NWBO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NWBO is unprofitable, but has reduced losses over the past 5 years at a rate of 7% per year.
Accelerating Growth: Unable to compare NWBO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NWBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: NWBO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.